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REVIEW ARTICLE 
Potential biomarker of neutrophil extracellular traps in 
venous thromboembolism: a systematic review  
Eka Prasetya Budi Mulia, Ivana Purnama Dewi, Mohammad Budiarto
BACKGROUND 
Neutrophil extracellular traps (NETs) are a network of extracellular 
DNA produced by activated neutrophils to trap and disarm microbes. 
NETs increase the formation of thrombus by forming a network 
frame that activates platelets and initiates coagulation. NETs were 
involved in the thrombogenic process and have been reported in 
various animal models. However, the evidence of NETs’ role in venous 
thromboembolism (VTE) development in humans is still scarce. This 
review aims to discover the relationship between NETs and VTE risk. 
METHODS 
We performed literature search to identify relevant available articles 
from PubMed, Cochrane Library, MEDLINE, EMBASE, Clinical Key 
between October 2009 until October 2019. The inclusion criteria 
were: clinical trials published in English, involving humans as subjects, 
conducted within the past ten years, and had available and accessible 
full-text. In addition, Newcastle Ottawa Scale (NOS) was used to 
assess evidence quality.  
RESULTS 
Four studies with a total of 1,430 patients, i.e. three case controls and 
one cohort, met our eligibility criteria. All four studies' quality was 
good. One study of cancer patients demonstrated that NETs increase 
VTE risk, two other studies demonstrated NETs correlate with deep 
vein thrombosis (DVT), and another study demonstrated there were 
increasing NETs in residual vein obstruction (RVO) and increased D-
dimer. All four studies found a significant association of NETs and 
VTE occurrence (p=0.003; p=0.018; p<0.01; p<0.001, respectively). 
CONCLUSIONS 
NETs are associated with an increased VTE risk. Further studies are 
necessary to determine the NETs’ role in VTE as a diagnostic 
biomarker or target of therapy 
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INTRODUCTION 
Venous thromboembolism (VTE), including 
pulmonary embolism (PE) and deep vein 
thrombosis (DVT), is a common cause of 
morbidity and premature mortality worldwide, 
but our knowledge in diagnosing and treating 
these diseases is limited.1 A recent study 
estimated that in the United States, total 
annual VTE cases reached more than 900,000, 
by which more than 250,000 were fatal.2 The 
average yearly attack rates of VTE related and 
unrelated to hospitalization were 282 and 8 
per 10,000 person-years, respectively. A 
multicenter study in Europe involving six 
countries reported an estimated annual 
465,715 DVT cases, 295,982 PE events, and 
370,012 VTE-related deaths.2 In Asia, the 
incidence of VTE  ranging from 14 to 57 cases 
per 100,000 patient-years.3–6 Despite advances 
in vascular biology and medicine, VTE's 
incidence has not declined in the last 25 years.2  
The standard protocol for the diagnosis of 
patients with VTE is to use a D-dimer 
biomarker to exclude VTE diagnosis, while 
compression ultrasound has been the gold 
standard for diagnosing DVT and Computed 
Tomography (CT) angiography for PE 
diagnosis.7,8 However, all of these diagnostic 
modalities have limitations such as being less 
specific, require a long time, uneven 
availability, and are quite expensive. Thus, an 
investigation of new diagnostic biomarkers to 
function as early identification of patients at 
low or high risk of first diagnosed and 
recurrent VTE is needed to enable immediate 
diagnosis and assessment of therapy. 
Venous thromboembolism is 
epidemiologically related to inflammatory 
diseases, such as infections, cancer, and 
autoimmune disorders. Acute infections and 
autoantibody against prothrombin 11 and 
phospholipid are risk factors for PE and DVT.9 
The incidence of malignancy and venous 
thrombosis also has been described in the 19th 
century. More recently, VTE and mortality risk 
is associated with an increase in neutrophils in 
cancer receiving chemotherapy.10 Neutrophils 
are the most numerous inflammatory cells and 
have recently emphasized their significance in 
DVT in animal studies.11–13  
Neutrophils are the first leukocytes that came 
to the site of infection and neutralized 
phagocytic bacteria.14 In phagosomes, 
microbes are killed by reactive oxygen species 
(ROS) and high concentrations of antimicrobial 
proteins. Neutrophils produce neutrophil 
extracellular traps (NETs) to trap and 
neutralize microorganisms in extracellular 
space. NETs are whole chromatin fiber 
scaffolds with antimicrobial proteins, ideal for 
maintaining large numbers of microbes.15 
NETs also encourage the formation of 
thrombus by serving as a network frame to 
activate platelets and initiate coagulation.16  
Neutrophil extracellular traps productions had 
been studied in thrombosis models of inferior 
vena cava in baboons’ iliac veins and Peptidyl 
arginine deiminase-4 (PAD4)-knockout mice. 
Studies revealed higher levels of plasma 
deoxyribonucleic acid (DNA) and NETs in 
venous thrombi, greater thrombus size/rate 
with higher von Willebrand factor (vWF) 
activation recruitment of platelet. Of note, 
histone infusion accelerates the thrombosis 
process while cleavage of NETs by 
Deoxyribonuclease 1 (DNase1) or heparin 
reduces the process.17-18 The thrombogenesis 
role of NETs has been documented in animals 
with various settings of thrombosis. However, 
evidence of NETs’ role in the risk of developing 
VTE in humans is still scarce. This review aims 
to discover whether NETs are correlated with 
VTE risk. 
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METHODS 
This systematic review was conducted using a 
predetermined protocol following “Preferred 
Reporting Items for Systematic Reviews and 
Meta-Analyses” (PRISMA) guidelines.19 1). The 
review was carried out in a series of steps: (i) 
searching the database for published articles, 
(ii) quality assessment for each obtained 
articles, (iii) extraction of data from tables and 
graphs, and (iv) interpretation and summary of 
findings. A meta-analysis of the data obtained 
could not be carried out because of the 
heterogeneity and broad diversity of study 
settings across the included literature. Thus, 
we provided the synthesis and findings of our 
review as a narrative summary. 
DATABASE SEARCH FOR IDENTIFICATION OF 
RELEVANT STUDIES  
We performed a literature search to identify 
relevant available articles from PubMed, 
Clinical Key, MEDLINE, EMBASE, Cochrane 
Library using subject terms “neutrophil 
extracellular traps”, “NETS”, “venous 
thromboembolism”, “VTE”, “pulmonary 
embolism”, “PE”, “deep vein thrombosis”, and 
“DVT. Search parameters were limited to a 
clinical trial, within the last 10 years (October 
2009 to October 2019), and full-text 
availability. Only English language was 
included. Manual searches of bibliographies 
and references were conducted. All three 
authors independently conducted searches. 
Abstracts for all results were reviewed, and 
relevant studies were selected for further 
review. Any disagreement in screening, 
extraction, and analysis of data was resolved 
by discussion. 
REVIEW METHODS AND STUDY SELECTION  
We included all studies enrolling the general 
population whose study participants had 
undergone an examination of NETS or 
biomarker of NETS formation with VTE 
incidence as an outcome. This review excluded 
review articles, descriptive studies, non-
English language articles, commentaries, 
letters, studies with non-human subjects, 
incompatibility of biomarkers with NETS 
formation, and studies with outcomes without 
VTE. Our search resulted in 108 articles, and 
ten more relevant articles were added from 
the bibliography, reference lists, and related 
citations of the primary articles, with a total of 
128.  Of the citations received, 82 duplicates 
were issued, leaving 46 articles, as illustrated 
in figure 1. All articles were screened by two 
independent reviewers (EPBM and IPD) based 
on inclusion and exclusion criteria. 
Of the 46 records after the removal of 
duplicates, the examination of titles and 
abstracts of the latter according to eligibility 
criteria resulted in the removal of 37 additional 
articles, leaving nine articles. A complete 
reading of the entire contents of the last 
number of papers further excluded five 
additional articles because biomarkers and 
outcomes did not address the review's aim 
sufficiently, thus, leaving four studies for 
consideration.  
DATA EXTRACTION AND QUALITY ASSESSMENT 
Data were extracted by two authors (EPBM 
and IPD) independently, then reviewed and 
validated by the third author (MB). All four 
studies were classified according to 
author/year, country/setting, the 
methodology of the study, sample size, 
statistical analysis, and outcome. The authors 
also conducted an assessment of the quality of 
each research article. We assessed the quality 
of the methods and research of studies by 
using Newcastle Ottawa Quality Assessment 
Scale (NOS) using predefined criteria, namely: 
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selection (representativeness of population), 
comparability (adjustment for confounders), 
and ascertainment of the outcome. The NOS 
allocates a maximum of four points for 
selection, two points for comparability, and 
three points for the outcome. Nine points of 
NOS reflects the highest study quality. 
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RESULTS 
Four studies with a total of 1430 patients met 
all inclusion and exclusion criteria. Three were 
of case-control and one was a prospective 
cohort study. The sample size varied between 
studies. The setting of research was well 
described in all publications. In Table 1, the 
research setting was either classified as a 
hospital or academic medical center (utilizing 
laboratory). The outcome of the studies was 
the incidence of VTE (Table 1). 
In spite of the fact that all of the articles were 
published in peer-reviewed journals in this 
review, we still carried out the examination of 
the methodological quality using NOS. The 
four qualifying reports good quality in all of 
the studies, as shown in table 2. 
There are several biomarkers of NETS 
formation that are different from each study, 
namely: citrullinated histone H3,20 circulating 
nucleosome and activated neutrophils,21 
plasma DNA,22 and neutrophil adhesion with 
inflammatory cytokines.23 All biomarkers were 
measured at baseline only, with no 
longitudinal measurements reported. One 
study used a specific population of cancer 
patients,20 while 3 others did not mention 
special populations.21–23 One study of cancer 
patient demonstrated that NETs increase VTE 
risk,20 two other studies demonstrated NETs 
correlate with DVT,21-22 and one study 
demonstrated there is increasing NETs in 
residual vein obstruction (RVO) and increased 
D-dimer.23 Table 3 showed that all four studies 
found a significant association of NETs and 
VTE occurrence (p=0.003; p=0.018; p<0.01; 
p<0.001). Two studies used DVT as an 
outcome; one study used VTE in general as an 
outcome, while the rest used residual vein 
obstruction and increased D-dimer as an 
outcome. Increased biomarkers of NET 
formation were correlated with a threefold 
risk of DVT and biomarker of NETs formation is 
increased in DVT patients and correlates with 
DVT biomarkers.21–23
 
Table 1 Description of the studies 
Author (year) Country/Setting Method Subject (n) % VTE 
Mauracher et al. (2018)20 Austria/ Medical University Cohort 946 9.4 
Zapponi et al. (2014)23 Brazil/ Medical University Case 
Control 
58 50 
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Table 2 Quality assessment of studies using NOS 
Author (year) Selection Comparability Outcome/Exposure Summary 
Mauracher et al. (2018)20 4 2 3 9 
Zapponi et al. (2014)23 4 2 3 9 
Diaz et al. (2013)22 4 2 2 8 
van Montfoort et al. (2013)21 4 2 3 9 
 




OR; 95% Confidence 
Interval (CI);  
P-value 
Outcome 




1.13; 95%CI 1.04–1.22; 
p=0.003 
Biomarker of NETs 
formation is associated 
with VTE development in 
cancer patients. 




24.68 vs 19.29 vs 
18.23**; p=0.018 
Increased biomarkers of 
NETs formation profile 
among patients with 
RVO and increased D-
dimer. 
Diaz et al. (2013)22 plasma DNA 57.7±6.3 vs 23.9±2.1 vs 
17.9±3.5*; p<0.01 
Biomarker of NETs 
formation is increased in 
DVT patients and 
correlates with DVT 
biomarkers. 






3.0; 95%CI 1.5–3.9; 
p<0.001 
Increased biomarkers of 
NETs formation were 
correlated with a 
threefold risk of DVT. 
data are expressed as 
*mean ± SD 
** median % adhesion 
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DISCUSSION 
Significant correlations between NETs and the 
incidence of VTE were demonstrated in all 
included studies. Citrullinated histone H3 
(H3Cit) has been proposed as a target 
biomarker, which reflects the formation of 
NET.24,25 Mauracher et al. mentioned cancer 
patients with elevated H3Cit levels 
experiencing higher cumulative VTE events 
than patients with H3Cit levels under this limit 
with a 2-year risk of 14.5% and 8.5%, 
respectively. Competing-risk regression 
analysis showed that for each increase in H3Cit 
levels of 100 ng / mL, there is a relative 
increase of 13% in the risk of VTE 
(subdistribution hazard ratio [SHR] 1.13; 95% 
CI 1.04-1.22). This relationship remained after 
adjustment for tumor site with very high VTE 
risk and high VTE risk, dissolved P-selectin 
levels, and D-dimer levels.20  
Histones are the most abundant protein in 
NETs. Histones are positively charged proteins 
that have the function to wrap DNA in the 
nucleus. This helps regulate the activation of 
platelet and thrombin in a dose-dependent 
manner.26 Platelets reveal several 
characteristics associated with activation such 
as aggregation, phosphatidylserine 
presentation, and P-selectin surface 
expression after treatment with histones.27 
Importantly, the compilation of histones 
complexes with DNA (such as those 
encountered in NETs), their ability to support 
platelet and generation of thrombin is 
strengthened.27 It has also been proposed that 
histone contributes to thrombin activation by 
isolating protein C and thrombomodulin and 
preventing the activation of thrombomodulin-
dependent protein C.28 Varied experiments in 
animal models showed that intravenous 
histones promote DVT risk in the context of 
inferior vena cava in mice.7 
 The population used in the study by 
Mauracher et al. is cancer patients.20 Cancer 
populations have an increased risk of VTE. A 
review by Horsted et al. stated that each year, 
VTE develops in more than 1% of cancer 
populations, but it differs significantly by time 
since diagnosis, type of cancer, stage of the 
disease, and treatment modality. Horsted et al. 
also stated that brain and pancreatic cancer 
had the highest risk of VTE.29 Tumor cells 
release cell-free DNA, growth factors, and 
procoagulant factors, which increase VTE. 
These factors include tissue factor (TF)-
positive microvesicles, granulocyte-colony 
stimulation factors (G-CSF), thrombopoietin 
(TPO), and IL-6. The release of G-CSF enhances 
the release of NETs from neutrophils and the 
expression of tissue factors by monocytes. 
Other drugs, including chemotherapy used to 
treat cancer, can also injure the endothelium 
and increase the level of plasma cell-free DNA, 
which may contribute to the mechanism of 
cancer-related thrombosis.30 
Van Montfoort et al. explore the relationship 
between elastase complex - α1-antitrypsin 
(EA) and nucleosomes, and the presence of 
DVT. Activation of neutrophils consequently 
leads to the NETs formation and nucleosome 
exposure to NETs contributes to in vivo 
coagulation activation and DVT development. 
Activated neutrophils were measured by EA. 
Patients with nucleosome levels more than 
80th percentile from controls had an increase in 
DVT risk compared to patients with levels less 
than equal 80th percentile (OR 3.0; 95% CI 1.5-
3.9). Besides, patients with EA complex levels 
more than 80th percentile from controls had an 
increase in DVT risk compared to patients with 
levels less than equal 80th percentile (OR 2.4; 
95% CI 1.5-3.9). Increased levels of EA complex 
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and circulating nucleosomes are associated 
with a threefold DVT risk, and the relationship 
remains the same after adjusting for potential 
confounders (smoking, malignancy, recent 
hospitalization, and recent immobilization). 
This risk increased with a higher level of EA and 
nucleosomes, showing a relationship between 
circulating nucleosomes, activated 
neutrophils, and DVT in a dose-dependent 
way.21 
Diaz et al. showed that circulating DNA (a 
surrogate marker for NETs) was increased in 
patients with DVT significantly, compared with 
patients without DVT (57.7 ± 6.3 vs. 17.9 ± 3.5 
ng/mL; p<0.01 ) and controls (57.7 ± 6.3 vs. 23.9 
± 2.1 ng/mL; p<0.01). Strong positive 
correlations were found with D-dimers, C-
reactive protein, vWF, myeloperoxidase/MPO, 
and Wells scores, and also strong negative 
correlations with disintegrin and 
metalloproteinase with type 1 
thrombospondin motifs, member 13 
(ADAMTS13) and ADAMTS13/vWF ratio. A 
strong relationship between plasma DNA and 
the presence of DVT was showed in logistic 
regression analysis (receiver operating 
characteristics/ROC curve 0.814).22 
Plasma contains circulating DNA (cDNA) and is 
increased in cardiovascular, inflammatory, and 
thromboembolic disorders. In vivo and in vitro 
data showed the vital role of cDNA in 
thrombosis and inflammation. DNase infusion 
reduces tissue inflammation and prevents 
thrombus formation in murine models by 
decreasing cDNA.12,31 Circulating DNA may be 
produced from dead cells and release of NETs 
from neutrophils, which is described as DNA 
fibers that contain enzymes released from 
neutrophil granules and histones. A study by 
Jiménez-Alcázar et al. showed that cDNA 
levels increased in patients with VTE compared 
with healthy controls. However, the 
relationship of cDNA to VTE level and outcome 
is poorly understood. They measured cDNA 
and nucleosomes as well as plasma circulating 
NETs from acute VTE patients. Their study 
suggested that cDNA levels but not NETs 
showed the level of inflammation and may 
function as a biomarker for stratification of 
patients with VTE who are at risk of death.32  
Fibronectin (FN) is a high molecular weight 
plasma glycoprotein produced by hepatocytes 
from the extracellular matrix that binds to 
integrins (membrane-spanning receptor 
proteins). Fibronectin plays a vital role in many 
cellular processes, including tissue repair, 
embryogenesis, cell migration/adhesion, and 
blood clotting. Because fibronectin is on the 
surface of endothelial cells and is secreted into 
the cell matrix, the adhesive properties of FN 
are modulated and enhanced by cell retaining 
to collagen or proteoglycan substrates.33 
Similar neutrophil adhesive properties of 
fibronectin (FN) between VTE and control 
patients were demonstrated in a study by 
Zapponi et al. Subgroup evaluation of patients 
who showed high D-dimer levels and residual 
venous occlusion (RVO) (n = 15; 51%), a 
significant increase in neutrophil adhesive 
properties when compared with the controls 
and the remaining patients could be observed, 
respectively (24.68%, 19.29%, 18.23%, p = 
0.0179).23 
For average-risk studies, the prevalence of VTE 
varied between 9.4%20 to 50%21,22. Some 
studies use case-control designs that usually 
use case and control with almost the same 
comparison; therefore, three studies showed a 
VTE prevalence of around 50%. One cohort of 
cancer patient showed that NETs increase VTE 
risk (9.4%), two case-controls showed NETs 
correlate with DVT (45% and 50%),21,22 and one 
case study showed there is increasing NETs in 
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RVO and increased D-dimer with 50% 
prevalence.23 
 Several limitations of our study include non-
random trial assignments, various populations, 
and small sample sizes. Four included studies 
also using various biomarkers in NETs 
measurement and having various study 
outcomes. 
CONCLUSIONS 
Neutrophils' role in thrombogenesis is the 
recent advances in understanding VTE. 
Neutrophils are unique and essential; NETs 
formation has been shown to have a causative 
role in increasing VTE risk. More research is 
necessary to determine the NETs’ role in VTE 






1. Rahimi K, Bhala N, Kamphuisen P, et al. Effect of 
Statins on Venous Thromboembolic Events: A 
Meta-analysis of Published and Unpublished 
Evidence from Randomised Controlled Trials. 
Rosendaal FR, ed. PLoS Med. 2012;9(9):e1001310. 
doi:10.1371/journal.pmed.1001310 
2. Rodriguez AL, Wojcik BM, Wrobleski SK, et al. 
Statins, inflammation and deep vein thrombosis: a 
systematic review. J Thromb Thrombolysis. 
2012;33(4):371-382. doi:10.1007/s11239-012-0687-
9 
3. Jang MJ, Bang S-M, Oh D. Incidence of venous 
thromboembolism in Korea: from the Health 
Insurance Review and Assessment Service 
database. J Thromb Haemost. 2011;9(1):85-91. 
doi:10.1111/j.1538-7836.2010.04108.x 
4. Molina JAD, Jiang ZG, Heng BH, Ong BKC. Venous 
thromboembolism at the National Healthcare 
Group, Singapore. Ann Acad Med Singapore. 
2009;38(6):470-478. 
http://www.ncbi.nlm.nih.gov/pubmed/19565096. 
Accessed August 18, 2019. 
5. Liu HSY, Kho BCS, Chan JCW, et al. Venous 
thromboembolism in the Chinese population--
experience in a regional hospital in Hong Kong. 
Hong Kong Med J = Xianggang yi xue za zhi. 
2002;8(6):400-405. 
http://www.ncbi.nlm.nih.gov/pubmed/12459595. 
Accessed August 18, 2019. 
6. Lee C-H, Lin L-J, Cheng C-L, Kao Yang Y-H, Chen J-Y, 
Tsai L-M. Incidence and cumulative recurrence rates 
of venous thromboembolism in the Taiwanese 
population. J Thromb Haemost. 2010;8(7):1515-
1523. doi:10.1111/j.1538-7836.2010.03873.x 
7. Mazzolai L, Aboyans V, Ageno W, et al. Diagnosis 
and management of acute deep vein thrombosis: a 
joint consensus document from the European 
Society of Cardiology working groups of aorta and 
peripheral vascular diseases and pulmonary 
circulation and right ventricular function. Eur Heart 
J. 2018;39(47):4208-4218. 
doi:10.1093/eurheartj/ehx003 
8. Konstantinides S V., Torbicki A, Agnelli G, et al. 
2014 ESC Guidelines on the diagnosis and 
management of acute pulmonary embolism. Eur 
Heart J. 2014;35(43):3033-3080. 
doi:10.1093/eurheartj/ehu283 
9. Fuchs TA, Brill A, Wagner DD. Neutrophil 
extracellular trap (NET) impact on deep vein 
thrombosis. Arterioscler Thromb Vasc Biol. 
2012;32(8):1777-1783. 
doi:10.1161/ATVBAHA.111.242859 
10. Connolly GC, Khorana AA, Kuderer NM, Culakova E, 
Francis CW, Lyman GH. Leukocytosis, thrombosis 
and early mortality in cancer patients initiating 
chemotherapy. Thromb Res. 2010;126(2):113-118. 
doi:10.1016/j.thromres.2010.05.012 
75
Malta Medical Journal     Volume 32 Issue 03 2020           
11. von Brühl M-L, Stark K, Steinhart A, et al. 
Monocytes, neutrophils, and platelets cooperate to 
initiate and propagate venous thrombosis in mice 
in vivo. J Exp Med. 2012;209(4):819-835. 
doi:10.1084/jem.20112322 
12. Brill., Fuchs TA, Savchenko AS, et al. Neutrophil 
extracellular traps promote deep vein thrombosis 
in mice. J Thromb Haemost. 2012;10(1):136-144. 
doi:10.1111/j.1538-7836.2011.04544.x 
13. Fuchs TA, Brill A, Duerschmied D, et al. Extracellular 
DNA traps promote thrombosis. Proc Natl Acad Sci 
U S A. 2010;107(36):15880-15885. 
doi:10.1073/pnas.1005743107 
14. Kobayashi SD, Malachowa N, DeLeo FR. Neutrophils 
and Bacterial Immune Evasion. J Innate Immun. 
2018;10(5-6):432-441. doi:10.1159/000487756 
15. Manfredi AA, Ramirez GA, Rovere-Querini P, 
Maugeri N. The Neutrophil’s Choice: Phagocytose 
vs Make Neutrophil Extracellular Traps. Front 
Immunol. 2018;9:288. 
doi:10.3389/FIMMU.2018.00288 
16. Laridan E, Martinod K, De Meyer S. Neutrophil 
Extracellular Traps in Arterial and Venous 
Thrombosis. Semin Thromb Hemost. 
2019;45(01):086-093. doi:10.1055/s-0038-1677040 
17. Rao AN, Kazzaz NM, Knight JS. Do neutrophil 
extracellular traps contribute to the heightened 
risk of thrombosis in inflammatory diseases? World 
J Cardiol. 2015;7(12):829-842. 
doi:10.4330/wjc.v7.i12.829 
18. Sen I. Plasma DNA and Neutrophil Extracellular 
Traps (NET): A Novel Biomarker in Lower Limb 
Venous Thrombosis. J Thromb Circ Open Access. 
2018;02(02). doi:10.4172/2572-9462.1000109 
19. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA 
statement for reporting systematic reviews and 
meta-analyses of studies that evaluate healthcare 
interventions: explanation and elaboration. BMJ. 
2009;339. doi:10.1136/bmj.b2700 
20. Mauracher L-M, Posch F, Martinod K, et al. 
Citrullinated histone H3, a biomarker of neutrophil 
extracellular trap formation, predicts the risk of 
venous thromboembolism in cancer patients. J 
Thromb Haemost. 2018;16(3):508-518. 
doi:10.1111/jth.13951 
21. van Montfoort ML, Stephan F, Lauw MN, et al. 
Circulating Nucleosomes and Neutrophil Activation 
as Risk Factors for Deep Vein Thrombosis. 
Arterioscler Thromb Vasc Biol. 2013;33(1):147-151. 
doi:10.1161/atvbaha.112.300498 
22. Diaz JA, Fuchs TA, Jackson TO, et al. Plasma DNA is 
elevated in patients with deep vein thrombosis. J 
Vasc Surg Venous Lymphat Disord. 2013;1(4):341-
349. doi:10.1016/j.jvsv.2012.12.002 
23. Zapponi KCS, Mazetto BM, Bittar LF, et al. 
Increased adhesive properties of neutrophils and 
inflammatory markers in venous thromboembolism 
patients with residual vein occlusion and high D-
dimer levels. Thromb Res. 2014;133(5):736-742. 
doi:10.1016/j.thromres.2014.01.035 
24. Thålin C, Demers M, Blomgren B, et al. NETosis 
promotes cancer-associated arterial 
microthrombosis presenting as ischemic stroke 
with troponin elevation. Thromb Res. 2016;139:56-
64. doi:10.1016/j.thromres.2016.01.009 
25. Demers M, Krause DS, Schatzberg D, et al. Cancers 
predispose neutrophils to release extracellular 
DNA traps that contribute to cancer-associated 
thrombosis. Proc Natl Acad Sci U S A. 
2012;109(32):13076-13081. 
doi:10.1073/pnas.1200419109 
26. Carestia A, Rivadeneyra L, Romaniuk MA, Fondevila 
C, Negrotto S, Schattner M. Functional responses 
and molecular mechanisms involved in histone-
mediated platelet activation. Thromb Haemost. 
2013;110(5):1035-1045. doi:10.1160/TH13-02-0174 
27. Semeraro F, Ammollo CT, Morrissey JH, et al. 
Extracellular histones promote thrombin 
generation through platelet-dependent 
mechanisms: Involvement of platelet TLR2 and 
TLR4. Blood. 2011;118(7):1952-1961. 
doi:10.1182/blood-2011-03-343061 
28. Ammollo CT, Semeraro F, Xu J, Esmon NL, Esmon 
CT. Extracellular histones increase plasma thrombin 
generation by impairing thrombomodulin-
dependent protein C activation. J Thromb Haemost. 
2011;9(9):1795-1803. doi:10.1111/j.1538-
7836.2011.04422.x 
29. Horsted F, West J, Grainge MJ. Risk of Venous 
Thromboembolism in Patients with Cancer: A 
Systematic Review and Meta-Analysis. Cannegieter 
SC, ed. PLoS Med. 2012;9(7):e1001275. 
doi:10.1371/journal.pmed.1001275 
76
Malta Medical Journal     Volume 32 Issue 03 2020           
30. Hisada Y, Geddings JE, Ay C, Mackman N. Venous 
thrombosis and cancer: from mouse models to 
clinical trials. J Thromb Haemost. 2015;13(8):1372-
1382. doi:10.1111/jth.13009 
31. Garcia-Romo GS, Caielli S, Vega B, et al. Netting 
neutrophils are major inducers of type I IFN 
production in pediatric systemic lupus 
erythematosus. Sci Transl Med. 2011;3(73):73ra20. 
doi:10.1126/scitranslmed.3001201 
32. Jiménez-Alcázar M, Limacher A, Panda R, et al. 
Circulating extracellular DNA is an independent 
predictor of mortality in elderly patients with 
venous thromboembolism. PLoS One. 
2018;13(2):e0191150. 
doi:10.1371/journal.pone.0191150 
33. Pankov R, Yamada KM. Fibronectin at a glance. J 
Cell Sci. 2002;115(20):3861-3863. 
doi:10.1242/jcs.00059 
 
 
77
